CaltechAUTHORS
  A Caltech Library Service

GD2-Targeted Immunotherapy and Potential Value of Circulating microRNAs in Neuroblastoma

Gholamin, Sharareh and Miezaei, Hamed and Razavi, Seyed-Mostafa and Hassanian, Seyed Mahdi and Saadatpour, Leila and Masoudifar, Aria and ShahidSales, Soodabeh and Avan, Amir (2018) GD2-Targeted Immunotherapy and Potential Value of Circulating microRNAs in Neuroblastoma. Journal of Cellular Physiology, 233 (2). pp. 866-879. ISSN 0021-9541. http://resolver.caltech.edu/CaltechAUTHORS:20170206-082810423

Full text is not posted in this repository. Consult Related URLs below.

Use this Persistent URL to link to this item: http://resolver.caltech.edu/CaltechAUTHORS:20170206-082810423

Abstract

Neuroblastoma (NB) with various clinical presentation is a known childhood malignancy. Despite significant progress in treatment of NB afflicted patients, high risk disease is usually associated with poor outcome, resulting in long-term survival of less that 50%. Known as a disease most commonly originated form the nerve roots, the variants involved in NB imitation and progression remain to be elucidated. The outcome of low to intermediate risk disease is favorable whereas the high risk NB disease with dismal prognosis, positing the necessity of novel approaches for early detection and prognostication of advanced disease. Tailored immunotherapy approaches have shown significant improvement in high-risk NB patients. It has found a link between Gangliosides and progression of NB. The vast majority of neuroblastoma tumors express elevated levels of GD2, opening new insight into using anti-GD2 drugs as potential treatments for NBs. Implication of anti-GD2 monoclonal antibodies for treatment of high risk NBs triggers further investigation to unearth novel biomarkers as prognostic and response biomarker to guide additional multimodal tailored treatment approaches. A growing body of evidence supports the usefulness of miRNAs to evaluate high risk NBs response to anti-GD2 drugs and further prevent drug-related toxicities in refractory or recurrent NBs. miRNAs and circulating proteins in body fluids (plasma, and serum) present as potential biomarkers in early detection of NBs. Here, we summarize various biomarkers involved in diagnosis, prognosis and response to treatment in patients with NB. We further attempted to overview prognostic biomarkers in response to treatment with anti-GD2 drugs.


Item Type:Article
Related URLs:
URLURL TypeDescription
http://dx.doi.org/10.1002/jcp.25793DOIArticle
http://onlinelibrary.wiley.com/doi/10.1002/jcp.25793/abstractPublisherArticle
Additional Information:© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. Issue online: 6 November 2017; Version of record online: 23 May 2017; Accepted manuscript online: 1 February 2017; Manuscript Accepted: 10 January 2017; Manuscript Received: 9 January 2017.
Subject Keywords:Neuroblastoma; miRNAs; anti-GD2 drugs
Record Number:CaltechAUTHORS:20170206-082810423
Persistent URL:http://resolver.caltech.edu/CaltechAUTHORS:20170206-082810423
Official Citation:Gholamin S, Mirzaei H, Razavi S-M, et al. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma. J Cell Physiol. 2018;233:866–879. https://doi.org/10.1002/jcp.25793
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:74060
Collection:CaltechAUTHORS
Deposited By: Tony Diaz
Deposited On:06 Feb 2017 18:08
Last Modified:16 Nov 2017 16:03

Repository Staff Only: item control page